StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) shareholders

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
35.6%
1M of 4M shares
Institutional holders
24
10 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
2 buys · 24 sales
Net bought $513.53K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Ligand Pharmaceuticals Incorporated5,189,17749.90%13D (active) amendmentOct 30, 2026
Alexandra Wood (Canada) Inc.574,1879.53%13G (passive)Dec 13, 2024
Motif Pharmaceuticals Ltd.483,4068.40%13G (passive)Feb 21, 2024
Boswell Prayer Ltd
Joint filing with Rochelle Gross (8.20%)
471,5928.20%13G (passive)Feb 21, 2024
Aperture Healthcare Ventures Ltd.444,0707.70%13G (passive)Feb 21, 2024
Benuvia Operations, LLC
Joint filing with Darwin Richardson (6.70%)
384,2266.70%13G (passive)Feb 21, 2024
Maier Joshua Tarlow
Joint filing with 3i, LP (9.90%), 3i Management LLC (9.90%)
337,0269.90%13G (passive) amendmentMar 31, 2026
3i Management LLC
Joint filing with 3i, LP (9.90%), Maier Joshua Tarlow (9.90%)
318,8869.90%13G (passive) amendmentDec 31, 2025
3i, LP
Joint filing with 3i Management LLC (9.90%), Maier Joshua Tarlow (9.90%)
303,1389.90%13G (passive)Jul 1, 2025
Marc Bistricer
Joint filing with Murchinson Ltd. (9.10%)
280,0009.10%13G (passive)Sep 30, 2025
Neil Shahrestani
Joint filing with Ikarian Capital, LLC (7.70%)
256,5987.70%13G (passive) amendmentMar 31, 2026
Ezra Friedberg250,1218.30%13D (active) amendmentJul 1, 2025
Ikarian Capital, LLC
Joint filing with Neil Shahrestani (6.10%)
186,4086.10%13G (passive) amendmentSep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PTHSValueChange% of portfolio
AIGH Capital Management LLC329,0988.60%$9.30MNew0.59%
Murchinson Ltd.304,3027.95%$8.60M+7,9881.19%
Ikarian Capital, LLC256,5986.70%$7.25M–0.78%
Boothbay Fund Management, LLC101,9762.66%$2.88M+20,1180.04%
Vanguard Capital Management LLC97,1342.54%$2.75M+4,0410.00%
Cantor Fitzgerald, L. P.76,2461.99%$2.15M+34,8230.01%
J. Goldman & Co LP38,0750.99%$1.08M−12,3400.03%
Diadema Partners LP24,7730.65%$700.09K–0.09%
Wexford Capital LP22,3640.58%$632.01KNew0.08%
Knott David M Jr22,0730.58%$623.78K+1,0000.33%
Citadel Advisors LLC15,0460.39%$425.20KNew0.00%
Geode Capital Management, LLC14,6500.38%$414.01K−6400.00%
Pale Fire Capital SE12,9190.34%$365.09K–0.03%
1492 Capital Management LLC10,3800.27%$293.34KNew0.09%
Vanguard Fiduciary Trust Co9,8730.26%$279.01K+560.00%
State Street Corp9,8000.26%$276.95KNew0.00%
Persistent Asset Partners Ltd6,0070.16%$169.76K–0.05%
BlackRock, Inc.5,3240.14%$150.46KNew0.00%
UBS Group AG2,2170.06%$62.65K+1,4530.00%
China Universal Asset Management Co., Ltd.2,1600.06%$61.04KNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026241M35.6%10 / 72 / 30M0M
Q1 2026171M23.8%5 / 82 / 20M0M
Q4 2025151M23.5%4 / 100 / 30M0M
Q3 2025140M12.1%14 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

9 funds held PTHS in Q2 2026, 87% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PTHSValue% of fundAs of
Vanguard Total Stock Market Index Fund78,0082.04%$2.20M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund16,1280.42%$455.78K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund7,4640.19%$197.57K0.00%May 31, 2026
iShares Micro-Cap ETF4,9910.13%$141.05K0.01%Jun 30, 2026
Fidelity Total Market Index Fund2,0520.05%$54.32K0.00%May 31, 2026
Fidelity Series Total Market Index Fund1,9720.05%$52.20K0.00%May 31, 2026
Vanguard Institutional Total Stock Market Index Fund1,8180.05%$51.38K0.00%Jun 30, 2026
Vanguard Balanced Index Fund1,1800.03%$33.35K0.00%Jun 30, 2026
1290 VT Micro Cap Portfolio3330.01%$9.41K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Scott M. PleshaCEO and President, Director83,6782.19%Apr 1, 2026
Knuettel Francis IICFO, Treas & Secty40,8411.07%May 26, 2026
John M. GayChief Financial Officer30,5180.80%Apr 20, 2026
Sai RangaraoChief Commercial Officer30,5180.80%Apr 1, 2026
Matthew PaulsDirector13,5780.35%Oct 6, 2026
Ezra M. FriedbergDirector202,5565.29%Oct 6, 2026
Peter GreenleafDirector23,0870.60%Oct 6, 2026
Todd C. DavisDirector1,575,33141.15%Jun 15, 2026
Richard MalamutDirector28,4620.74%Apr 6, 2026
Richard B. BaxterDirector19,1080.50%Apr 1, 2026
Andrew J. EinhornDirector12,0000.31%Dec 29, 2025
Pharmaceuticals Inc LigandDirector, 10% owner1,500,00039.18%Dec 19, 2025
Chia-Lin SimmonsDirector––Apr 15, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Peter Greenleaf
Director
Oct 2, 2026Sale(10b5-1 plan)−797$21.17$16.87K23,087
Ezra M. Friedberg
Director
Oct 2, 2026Sale(10b5-1 plan)−558$20.72$11.56K80,484
Matthew Pauls
Director
Oct 2, 2026Sale(10b5-1 plan)−786$21.00$16.51K13,578
Matthew Pauls
Director
Jul 2, 2026Sale(10b5-1 plan)−692$26.00$17.99K14,458
Matthew Pauls
Director
Jul 2, 2026Sale(10b5-1 plan)−94$27.36$2.57K14,364
Ezra M. Friedberg
Director
Jul 2, 2026Sale(10b5-1 plan)−24$27.33$65681,042
Ezra M. Friedberg
Director
Jul 2, 2026Sale(10b5-1 plan)−534$26.03$13.90K81,066
Peter Greenleaf
Director
Jul 2, 2026Sale(10b5-1 plan)−85$27.27$2.32K23,884
Peter Greenleaf
Director
Jul 2, 2026Sale(10b5-1 plan)−712$26.00$18.51K23,969
Ezra M. Friedberg
Director
Jun 15, 2026Sale(10b5-1 plan)−59$27.94$1.65K81,600
Ezra M. Friedberg
Director
Jun 15, 2026Sale(10b5-1 plan)−224$27.12$6.07K81,659
Todd C. Davis
Director
Jun 11, 2026Buy+35,445$27.80$985.37K75,331
Todd C. Davis
Director
Jun 11, 2026Buy+503$28.73$14.45K75,834
Knuettel Francis II
CFO, Treas & Secty
May 22, 2026Returned to company−13,947––19,525
Knuettel Francis II
CFO, Treas & Secty
May 22, 2026Sale−1,500$26.84$40.26K11,316
Ezra M. Friedberg
Director
May 14, 2026Tax withholding−144$27.01$3.89K81,883
Richard Malamut
Director
Apr 2, 2026Sale(10b5-1 plan)−280$21.36$5.98K27,422
Richard Malamut
Director
Apr 2, 2026Sale(10b5-1 plan)−310$20.51$6.36K27,702
Matthew Pauls
Director
Apr 2, 2026Sale(10b5-1 plan)−415$20.52$8.52K15,521
Matthew Pauls
Director
Apr 2, 2026Sale(10b5-1 plan)−371$21.36$7.92K15,150
Ezra M. Friedberg
Director
Apr 2, 2026Sale(10b5-1 plan)−265$21.36$5.66K82,027
Ezra M. Friedberg
Director
Apr 2, 2026Sale(10b5-1 plan)−293$20.51$6.01K82,292
Peter Greenleaf
Director
Apr 2, 2026Sale(10b5-1 plan)−377$21.36$8.05K24,681
Peter Greenleaf
Director
Apr 2, 2026Sale(10b5-1 plan)−420$20.52$8.62K25,058
Andrew J. Einhorn
Director
Dec 23, 2025Award+12,000––12,000
Matthew Pauls
Director
Dec 10, 2025Gift−9,542––1,074
Ezra M. Friedberg
Director
Nov 25, 2025Sale−2,000$28.14$56.28K32,001
Ezra M. Friedberg
Director
Nov 25, 2025Sale−1$28.50$2932,000
Ezra M. Friedberg
Director
Nov 25, 2025Sale−2,000$28.01$56.02K30,000
Ezra M. Friedberg
Director
Nov 25, 2025Sale−5,999$28.00$167.97K34,001
Richard Malamut
Director
Nov 13, 2025Award+2,454––8,904
Matthew Pauls
Director
Oct 2, 2025Option exercise+2,123––10,616
Knuettel Francis II
CFO, Treas & Secty
Jul 2, 2025Award+33,472––33,472
Sai Rangarao
Chief Commercial Officer
Jul 2, 2025Award+30,518––30,518
Richard B. Baxter
Director
Jul 2, 2025Award+19,108––19,108
Scott M. Plesha
CEO and President, Director
Jul 2, 2025Award+83,678––83,678
Richard Malamut
Director
Jul 2, 2025Award+19,108––28,012
Ezra M. Friedberg
Director
Jul 2, 2025Award+19,108––82,585
Matthew Pauls
Director
Jul 2, 2025Award+25,478––25,478
Peter Greenleaf
Director
Jul 2, 2025Award+25,478––25,478
Todd C. Davis
Director
Jul 2, 2025Award+19,108––39,886
Matthew Pauls
Director
Jul 2, 2025Option exercise+8,493––8,493
Knuettel Francis II
Chief Financial Officer
Jul 1, 2025Conversion+10,000$10.00$100.00K10,000
Pharmaceuticals Inc Ligand
10% owner
Jul 1, 2025Conversion+1,500,000$10.00$15.00M1,500,000
Todd C. Davis
Director, 10% owner
Jul 1, 2025Conversion+1,500,000$10.00$15.00M1,500,000
Ezra M. Friedberg
Director
Jul 1, 2025Conversion+40,000$10.00$400.00K40,000
Ezra M. Friedberg
Director
Jul 1, 2025Conversion+40,000$10.00$400.00K40,000
Ezra M. Friedberg
Director
Nov 13, 2024Award+2,454––63,477
Todd C. Davis
Director
Nov 13, 2024Award+4,961––20,778
Knuettel Francis II
CEO, Pres., CFO, Treas & Secty
Sep 13, 2024Buy+3,500$0.97$3.40K547,710
Richard Malamut
Director
Sep 12, 2024Buy+10,400$0.94$9.78K91,565
Knuettel Francis II
CEO, Pres., CFO, Treas & Secty
Sep 12, 2024Buy+1,700$0.97$1.65K544,210
Knuettel Francis II
CEO, Pres., CFO, Treas & Secty
Sep 11, 2024Buy+5,500$0.94$5.17K542,510
Knuettel Francis II
CEO, Pres., CFO, Treas & Secty
Sep 10, 2024Buy+6,500$0.89$5.79K537,010
Knuettel Francis II
CEO, Pres., CFO Treas & Secty
Jun 28, 2024Gift−15,000––515,510
Knuettel Francis II
CEO, Pres., CFO Treas & Secty
Jun 28, 2024Gift−5,000––530,510
Richard Malamut
Director
Jun 14, 2024Award+6,450––6,450
Ezra M. Friedberg
Director
Jun 14, 2024Award+6,450––61,023
Todd C. Davis
Director
Jun 14, 2024Award+12,900––15,817
Ezra M. Friedberg
Director
Feb 21, 2024Buy+16,667$6.00$100.00K545,721

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
4.14%
0M shares short
Days to cover
2.0
At 0M shares a day
Change since last report
+11.4%
From 0M shares
Short volume, 20 days
60.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pelthos Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,230 shares on Oct 14, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Knuettel Francis II
Officer
May 22, 20261,720$46.63KMay 22, 2026Market

See a number that looks wrong?